The short version of REV-ERB agonist fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-07. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
Reactive neutrophilic cutaneous conditions constitute a spectrum of disease mediated by neutrophils, and typically associated with underlying diseases, such as inflammatory bowel disease and hematologic malignancy.
The reference values vary across studies, ranging from > 25 cm/s to > 35 cm/s. Values above 35 cm/s indicate the absence of arterial disease, values below 25 cm/s indicate arterial insufficiency, and values of 25–35 cm/s are indeterminate because they are less specific (see image below). The data obtained should be correlated with the degree of erection observed. If the peak systolic velocities are normal, the final diastolic velocities should be evaluated, those above 5 cm/s being associated with venogenic ED.
=== Role of chaperones === The autoprocessing of PIDD1 rate to induce the precise conformational state necessary for efficient self-cleavage. Hsp90 directly associates with full-length PIDD1 (FL-PIDD1), subsequently recruiting p23 to facilitate the stabilization and folding of PIDD1 into its active configuration. Hsp70, another key chaperone, binds not only to full-length PIDD1 (FL-PIDD1) but also to its cleavage fragments, PIDD-N and PIDD-C, although the specific role of this interaction is not yet fully understood. In addition to facilitating autoprocessing, Hsp90 plays a crucial role in maintaining PIDD1's stability and function, highlighting the importance of chaperones in controlling both PIDD1 self-cleavage and its overall protein levels. When Hsp90 is inhibited, PIDD1 undergoes rapid degradation through the E3 ubiquitin-protein ligase CHIP (also called STUB1), which appears to favor the ubiquitination of PIDD-C over PIDD-CC. CHIP directly interacts with both PIDD1 and Hsp70, suggesting that Hsp70 may also be involved in regulating PIDD1. Although the PIDDosome can form in vitro after temperature changes, and the dissociation of Hsp90 is required for this process, Hsp90s initial interaction is critical for PIDD1’s function. Interruption of the Hsp90-PIDD1 complex disrupts PIDD1 autoprocessing and its interactions with effector proteins.
A neuron is called identified if it has properties that distinguish it from every other neuron in the same animal—properties such as location, neurotransmitter, gene expression pattern, and connectivity—and if every individual organism belonging to the same species has exactly one neuron with the same set of properties. In vertebrate nervous systems, very few neurons are "identified" in this sense. Researchers believe humans have none—but in simpler nervous systems, some or all neurons may be thus unique. In vertebrates, the best known identified neurons are the gigantic Mauthner cells of fish. Every fish has two Mauthner cells, located in the bottom part of the brainstem, one on the left side and one on the right. Each Mauthner cell has an axon that crosses over, innervating (stimulating) neurons at the same brain level and then travelling down through the spinal cord, making numerous connections as it goes. The synapses generated by a Mauthner cell are so powerful that a single action potential gives rise to a major behavioral response: within milliseconds the fish curves its body into a C-shape, then straightens, thereby propelling itself rapidly forward. Functionally of this is a fast escape response, triggered most easily by a strong sound wave or pressure wave impinging on the lateral line organ of the fish. Mauthner cells are not the only identified neurons in fish—there are about 20 more types, including pairs of "Mauthner cell analogs" in each spinal segmental nucleus.
Sources: en.wikipedia.org
=== Distribution ratio === In solvent extraction, a distribution ratio (D) is often quoted as a measure of how well-extracted a species is. The distribution ratio is a measure of the total concentration of a solute in the organic phase divided by its concentration in the aqueous phase. The partition or distribution coefficient (Kd) is the ration of solute concentration in each layer upon reaching equilibrium. This distinction between D and Kd is important. The partition coefficient is a thermodynamic equilibrium constant and has a fixed value for the solute’s partitioning between the two phases. The distribution ratio’s value, however, changes with solution conditions if the relative amounts of A and B change. If we know the solute’s equilibrium reactions within each phase and between the two phases, we can derive an algebraic relationship between Kd and D. The partition coefficient and the distribution ratio are identical if the solute has only one chemical form in each phase; however, if the solute exists in more than one chemical form in either phase, then Kd and D usually have different values. Depending on the system, the distribution ratio can be a function of temperature, the concentration of chemical species in the system, and a large number of other parameters. Note that D is related to the Gibbs Free Energy (ΔG) of the extraction process. In solvent extraction, two immiscible liquids are shaken together. The more polar solutes dissolve preferentially in the more polar solvent, and the less polar solutes in the less polar solvent.
=== Adrenal === Angiotensin II acts on the adrenal cortex, causing it to release aldosterone, a hormone that causes the kidneys to retain sodium and lose potassium. Elevated plasma angiotensin II levels are responsible for the elevated aldosterone levels present during the luteal phase of the menstrual cycle.
Upon taking office in 2001, Bush stated his opposition to the Kyoto Protocol, an amendment to the United Nations Framework Convention on Climate Change which seeks to impose mandatory targets for reducing greenhouse gas emissions, citing that the treaty exempted 80% of the world's population and would have cost tens of billions of dollars per year. He also cited that the Senate had voted 95–0 in 1997 on a resolution expressing its disapproval of the protocol. In May 2001, Bush signed an executive order to create an interagency task force to streamline energy projects, and later signed two other executive orders to tackle environmental issues. In 2002, Bush proposed the Clear Skies Act of 2003, which aimed at amending the Clean Air Act to reduce air pollution through the use of emissions trading programs. Many experts argued that this legislation would have weakened the original legislation by allowing higher emission rates of pollutants than were previously legal. The initiative was introduced to Congress, but failed to make it out of committee. Later in 2006, Bush declared the Northwestern Hawaiian Islands a national monument, creating the largest marine reserve to date. The Papahānaumokuākea Marine National Monument comprises 84 million acres (340,000 km2) and is home to 7,000 species of fish, birds, and other marine animals, many of which are specific to only those islands. The move was hailed by conservationists for "its foresight and leadership in protecting this incredible area".
Sources: en.wikipedia.org
=== Saturation binding === Saturation analysis is used in various types of tissues, such as fractions of partially purified plasma from tissue homogenates, cells transfected with cloned receptors, and cells that are either in culture or isolated prior to analysis. Saturation binding analysis can determine receptor affinity and density. It requires that the concentration chosen must be determined empirically for a new ligand. There are two common strategies that are adopted for this type of experiment: Increasing the amount of radioligand added while maintaining both the constant specific activity and constant concentration of radioligand, or decreasing the specific activity of the radioligand due to the addition of an unlabeled ligand.
A 2017 study in The BMJ by Tim Dyson and Valeria Cetorelli concluded that "Saddam Hussein's government successfully manipulated the 1999 survey in order to convey a very false impression." In the case of Cuba, a declassified 1960 U.S. State Department memorandum by diplomat Lester D. Mallory argued that "every possible means should be undertaken promptly to weaken the economic life of Cuba" by denying money and supplies in order "to bring about hunger, desperation and overthrow of government." A 2025 study funded by the Center for Economic and Policy Research, authored by Mark Weisbrot, Francisco Rodríguez, and Silvio Rendón and published in The Lancet, estimated that unilateral sanctions by all parties—including those of the United States, United Nations, and European Union—were associated with as many as 564,258 deaths annually between 1971 and 2021. The study found "significant causal association between sanctions and increased mortality" with "the strongest effects for unilateral, economic, and US sanctions." Writing in Al Jazeera about this study, Jason Hickel, Dylan Sullivan, and Omer Tayyab estimated that unilateral sanctions imposed by the United States and European Union since 1970 were associated with approximately 38 million deaths worldwide, with more than half of the victims being children and the elderly, and that sanctions kill several times more people each year than die as direct casualties of war.
These findings extend the use of MPPT into dermatology and positive effects have been observed in hidradenitis suppurativa. The MPPT technology has been approved in the EU as a "treatment for wounds" and is currently the only wound product with this approval. Other medical devices for wounds are approved to have a certain effect on the wound, e.g. add moisture or remove wound exudate, but they are not recognised as treatments.
In 2011, food accounted for 70% of Indian retail, but was under-represented by organised retail. A.T. Kearney estimates India's organised retail had a 31% share in clothing and apparel, while the home supplies retail was growing between 20% and 30% per year. These data correspond to retail prospects prior to November announcement of the retail reform. It might be true that India has the largest number of shops per inhabitant. However, detailed figures are available for Belgium, the Netherlands, and Luxembourg. In Belgium, the number of outlets is approximately 8 per 1,000 inhabitants, while in the Netherlands it is 6 per 1,000 inhabitants. Therefore, the Indian figure must be significantly higher.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.